AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02374138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental stress management
Description: The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches.
Study NCT02374138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
Study NCT00886405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Description: Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
Study NCT04643561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travelan OTC
Description: 5 days of treatment with Travelan food supplement 3 times a day, blood will be drawn prior and after intervention
Study NCT03138655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusion.
Study NCT03234959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CareToy intervention
Description: Infants will perform goal directed activities inside the CareToy System
Study NCT03234959 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant Massage
Description: Infants will received IM by their parents
Study NCT03136822 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Dressing
Description: Standard dressing is applied for treatment of diabetic foot ulcers
Study NCT03280303 — intervention group
Intervention type: OTHER
Intervention: non-interventional
Study NCT04733261 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic mobility
Description: Therapist will manually make contact with Pisiform Hypothenar region and last three fingers among the underneath the costal cartilage of the 7th in the direction of 10 ribs. For the duration of participant's inhalation, the counselor drag softly within a upward course accompany the increase motion of the ribs. For the period of expiration, the counselor will deepens make contact with in the direction of the internal costal border. Taking place consequent breathing, the counselor wanted on the way to expand traction as well as slickly make deeper the contact.
Study NCT04733261 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Physiotherapy
Description: Patients allocated to the control group and interventional group received pulmonary rehabilitation two times a day beginning happening the day of entrance on the way to the intensive care unit. It consists of side-lying positioning with the head of the bed horizontal for at least 20 min with the most affected lung on chest x-ray positioned uppermost is also known as postural drainage, 4 sets of 6 cycles of expiratory chest wall vibrations , and airway suctioning at least three times through the endotracheal and tracheotomy tube disperse in the course of the management
Study NCT02931929 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 68Ga-NeoBOMB1, 2-vial kit
Description: intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
Study NCT03590769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: All subject will undergo PET/MRI scans pre-operatively, 1 day and 1 week post-operatively using FDG
Study NCT03219190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LST High School Online
Description: The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
Study NCT03865108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging
Description: This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
Study NCT03865108 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound imaging
Description: This standard of care procedure is being done for research purposes and used to collect information and measure the maternal and fetal anatomy.
Study NCT03865108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical speculum examination
Description: This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
Study NCT03865108 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cervical speculum examination
Description: This standard of care procedure is being done for research purposes and used to collect tissue and measure the strength and stiffness of cervix.
Study NCT04261972 — intervention group
Intervention type: GENETIC
Intervention: Next generation sequencing (NGS)
Description: NGS
Study NCT04077645 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Seated rest
Description: This group will be watching educational videos for the same amount of time as the intervention groups. An orientation session of 5 minutes will be held in the beginning. Participants will be watching videos on general health related topics, such as healthy eating, while being seated in a quiet room, free of distractions.
Study NCT03992742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial phase: personalized instant messaging (PIM)
Description: intervention Group participants will receive three months of personalized interaction through IM Apps (e.g. WhatsApp, WeChat). Our counsellors will trigger the conversation and encourage the participants to set a quit day. A total of pre-set 26 messages will be sent with the schedule of once daily for 1 week (the week across the quit date), 3 times a week for 4 weeks (2 weeks each before and after the week with quit date) and once a week for remaining 7 weeks. These messages covered generic information about the benefits of quitting, methods to avoid/ manage craving or withdrawal symptoms, and encouragement to quit and use SC services.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive PIM (subgroup C). Incomplete responders (smokers) will be randomized to continue PIM (subgroup B) or receive OCI (subgroup A).
Study NCT03992742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Second phase: optional cocktail interventions (OCI)
Description: For incomplete respondents (subgroup A) randomized to OCI, the available intervention options include multi-media messages, active referral plus financial incentive, phone counseling, family/peer support and medications (NRT). Participants will be guided by cessation counsellors at 1-month follow-up telephone survey to choose any combination of OCI based on their preference. If OCI participants cannot be followed up at 1-month, they will receive multi-media messages by default.
Study NCT03992742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Initial phase: regular instant messaging (RIM)
Description: Participants enrolled in the Control Group will receive regular messages via IM services (e.g. WhatsApp, WeChat) since initial contact and until 3-month after baseline with a tapering schedule: 1) Baseline to 4-week (1-month): 2 times/ week (8 in total); 2) 4-week to 12-week (2- \& 3-month): 1 time/week (8 in total).~SC messages will generally include benefits of SC, encouragement on abstinence and use of SC services, tips on avoiding/ handling craving and reminder of participating in telephone follow-up. A reminder to participate in the telephone follow-up will also be sent at 1-, 2-, 3- and 6-month, making up a total of 20 messages.~At the end of the initial phase (1-month), complete responders (quitters) will continue to receive RIM (subgroup F). Incomplete responders (smokers) will be second randomized to continue RIM (subgroup E) or receive PIM (subgroup D). Those who are unable to follow up at 1-month will be considered as nonresponsive to the intervention.
Study NCT03992742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Second phase: personalized instant messaging (PIM)
Description: For incomplete responders allocated to PIM (subgroup D), participants will receive the same intervention as the Group A delivered at the initial stage. Participants will receive two months of personalized interaction through IM application. Please refer to Intervention Group Initial phase: personalized instant messaging (PIM) for details.
Study NCT03992742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
Study NCT03992742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning leaflet
Description: The 2-sided color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
Study NCT03992742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Referral card
Description: The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans
Study NCT03992742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COSH booklet
Description: A general smoking cessation self-help booklet
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.025 mg, single dose, one dose
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.1 mg, single dose, one dose
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.25 mg, single dose, one dose
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 0.5 mg, single dose, one dose
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 1 mg, single dose, one dose
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 2 mg, single dose, one dose
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 3 mg, single dose, one dose
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 5 mg, single dose, one dose
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836
Description: Oral Solution, Oral, 8 mg, single dose, one dose
Study NCT00964912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, single dose, one dose
Study NCT04379791 — intervention group
Intervention type: OTHER
Intervention: Data collection from routine medical records
Description: Data collection from routine medical records for criteria for fracture related infections (FRI) and for wound complications. Data collection from routine medical records for risk factors.
Study NCT02602444 — intervention group
Intervention type: DRUG
Intervention: ticagrelor
Description: 180 mg loading dose
Study NCT02996292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional brackets
Description: Treating of crowding using traditional brackets
Study NCT02996292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active self-ligating brackets
Description: Treating of crowding using active self-ligating brackets
Study NCT02996292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive self-ligating brackets
Description: Treating of crowding using passive self-ligating brackets
Study NCT00776087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Monitoring provided by Biotronik ICD and CRT-D devices
Description: Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
Study NCT00776087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: No Home Monitoring
Description: Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
Study NCT01994291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal Injection supplied as:~* 10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.~* 6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.~* Adminstered once a month for 12 weeks
Study NCT01994291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks
Study NCT01994291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04634817
Description: Four 50mg tablets PF-04634817 once a day for 12 weeks.
Study NCT01994291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masked Sham Therapy
Description: Empty, needle-less syringe is used by the unmasked team once a month.
Study NCT03886415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: Jaktinib hydrochloride tablets 100mg bid dose group and Jaktinib hydrochloride tablets 200mg qd dose group
Study NCT04363827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine
Study NCT03136822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Dressing
Description: Standard dressing is applied for treatment of diabetic foot ulcers
Study NCT03136822 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMALIX
Description: DERMALIX, a class III Medical Device will be applied in addition to standard dressing
Study NCT01479010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100 mg subcutaneously daily
Description: Anakinra 100 mg subcutaneously daily
Study NCT03387566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB002.1M
Description: HB002.1M is a Vascular Endothelial Growth Factor Receptor Decoy.
Study NCT01660659 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomass Briquettes and Rocket stove
Description: Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
Study NCT03907553 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: targeted genome sequencing
Study NCT01009125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $2 cash
Description: $2 cash incentive will be included in the mailed survey
Study NCT01009125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: $5 cash
Description: $5 cash incentive will be included in the mailed survey
Study NCT01508858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
Study NCT01508858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: liraglutide
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
Study NCT01508858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
Study NCT01508858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
Study NCT01508858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levonorgestrel / ethinylestradiol
Description: One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
Study NCT01508858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levonorgestrel / ethinylestradiol
Description: One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
Study NCT02739204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
Study NCT00491998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V1512
Description: 6 doses of IMP at 2-hourly intervals
Study NCT00491998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V1512
Description: 3-hourly dosing
Study NCT00491998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: V1512 and Entacapone
Description: 4 doses of IMP and Entacapone at 3-hourly intervals
Study NCT01339429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: simplified negative pressure wound therapy device (Wound Pump device)
Description: A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
Study NCT04490538 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Conventional transthoracic echocardiographic examination at the intensive care unit.
Study NCT02088255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Static surface
Description: During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
Study NCT02088255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic surface
Description: During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
Study NCT04339127 — intervention group
Intervention type: OTHER
Intervention: Description and analysis
Description: Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
Study NCT02141243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lingual Frenotomy
Description: For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
Study NCT02141243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Labial Frenotomy
Description: For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
Study NCT02141243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
Study NCT03462264 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scoliogold App
Description: The mobile application will include a list of the specific exercises that the patient has to complete on a daily basis. It will have a start/stop button which the patient presses at the beginning and the end of each time that they complete their home exercise programme. This will get logged on to their application which can be accessed by the researcher to monitor home exercise compliance.
Study NCT03462264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Formatted Diary
Description: The pre-formatted diary will prompt the date, start time, end time and a list exercises that the patient has completed that day that the patient will be requested to fill out.
Study NCT01899300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metal Stent (WallFlex™ Esophageal RX)
Study NCT03526237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 24 week community based DPP Group Lifestyle Balance Program
Description: a) 12 weekly peer group (adapted Group Lifestyle Balance Program) sessions followed by 3 monthly group maintenance sessions held in Public Housing locations; b) Individual coaching and patient activation during 24 week period; 2) Community Outreach Care Coordination: Referral, navigation assistance, patient activation, and cross-linkage to FQHC services.
Study NCT03526237 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-List Control community based DPP Group Lifestyle Balance Program
Description: Control arm participants will receive: 1) Usual care in FQHC/primary care clinic 2) Individual counseling about pre-diabetes risk at baseline; mailed written NIDDK patient education materials (weight loss, physical activity, nutrition) at weeks 6, 12, 18; 2) At the end of the 24 week intervention, the wait list control arm will be invited to participate and receive the group based DPP sessions.